EUVIMEDEUVIMED entdecken
Open Access

Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy

Guangyuan Li iD, Shweta Mahajan iD, Siyuan Ma iD, Erin D Jeffery iD, Xuan Zhang iD, Anukana Bhattacharjee iD, Meenakshi Venkatasubramanian, Matthew T Weirauch iD, Emily R Miraldi iD, H Leighton Grimes iD, Gloria M Sheynkman, Tamara Tilburgs iD und 1 weitere

Science Translational Medicine · 17.01.2024 · 16 (730)

DOI: 10.1126/scitranslmed.ade2886 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 17.01.2024. Verfasst von Guangyuan Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. Hauptthemen laut MEDLINE: Melanoma, Neoplasms. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHGRI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has emerged as a crucial strategy to combat cancer by “reprogramming” a patient’s own immune system. Although immunotherapy is typically reserved for patients with a high mutational burden, neoantigens produced from posttranscriptional regulation may provide an untapped reservoir of common immunogenic targets for new targeted therapies. To comprehensively define tumor-specific and likely immunogenic neoantigens from patient RNA-Seq, we developed Splicing Neo Antigen Finder (SNAF), an easy-to-use and open-source computational workflow to predict splicing-derived immunogenic MHC-bound peptides (T cell antigen) and unannotated transmembrane proteins with altered extracellular epitopes (B cell antigen). This workflow uses a highly accurate deep learning strategy for immunogenicity prediction (DeepImmuno) in conjunction with new algorithms to rank the tumor specificity of neoantigens (BayesTS) and to predict regulators of mis-splicing (RNA-SPRINT). T cell antigens from SNAF were frequently evidenced as HLA-presented peptides from mass spectrometry (MS) and predict response to immunotherapy in melanoma. Splicing neoantigen burden was attributed to coordinated splicing factor dysregulation. Shared splicing neoantigens were found in up to 90% of patients with melanoma, correlated to overall survival in multiple cancer cohorts, induced T cell reactivity, and were characterized by distinct cells of origin and amino acid preferences. In addition to T cell neoantigens, our B cell focused pipeline (SNAF-B) identified a new class of tumor-specific extracellular neoepitopes, which we termed ExNeoEpitopes. ExNeoEpitope full-length mRNA predictions were tumor specific and were validated using long-read isoform sequencing and in vitro transmembrane localization assays. Therefore, our systematic identification of splicing neoantigens revealed potential shared targets for therapy in heterogeneous cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNeoplasmsHumansAntigens, NeoplasmT-LymphocytesPeptidesImmunotherapy

Substanzen

Antigens, NeoplasmPeptides

Autor:innen und Institutionen

  • Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
  • Department of Biomedical Informatics, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
  • Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
  • Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22903, USA.
  • Department of Computer Science, University of Cincinnati, Cincinnati, OH 45229, USA.
  • Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.

ORCID-Profile: Guangyuan Li, Shweta Mahajan, Siyuan Ma, Erin D Jeffery, Xuan Zhang, Anukana Bhattacharjee, Matthew T Weirauch, Emily R Miraldi, H Leighton Grimes, Tamara Tilburgs, Nathan Salomonis

Förderung

  • NCI NIH HHS
  • NHGRI NIH HHS
  • NIDDK NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Li, G., Mahajan, S., Ma, S., Jeffery, E. D., Zhang, X., Bhattacharjee, A., Venkatasubramanian, M., Weirauch, M. T., Miraldi, E. R., Grimes, H. L., Sheynkman, G. M., Tilburgs, T., & Salomonis, N. (2024). Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy. Science Translational Medicine, 16(730). https://doi.org/10.1126/scitranslmed.ade2886

Vancouver

Li G, Mahajan S, Ma S, Jeffery ED, Zhang X, Bhattacharjee A, et al. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy. Science Translational Medicine. 2024;16(730). doi:10.1126/scitranslmed.ade2886

BibTeX
@article{Li2024,
  author = {Li, Guangyuan and Mahajan, Shweta and Ma, Siyuan and Jeffery, Erin D and Zhang, Xuan and Bhattacharjee, Anukana and Venkatasubramanian, Meenakshi and Weirauch, Matthew T and Miraldi, Emily R and Grimes, H Leighton and Sheynkman, Gloria M and Tilburgs, Tamara and Salomonis, Nathan},
  title = {Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {730},
  doi = {10.1126/scitranslmed.ade2886}
}
Kostenlos starten →